Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof
OwnerJan Holgerssoninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for cancer vaccine immunogenicity using lewis Y mucin-immunoglobulin fusion proteins.
Claims46
A purified tumor vaccine comprising a polypeptide wherein the polypeptide is glycosylated by a α1,2 fucosyltransferase and α1,3 fucosyltransferase.
A purified tumor vaccine comprising, a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide comprises a tumor-associated carbohydrate epitope and the second polypeptide comprises an immune response stimulator polypeptide.
A purified tumor vaccine comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is glycosylated by an α1,2 fucosyltransferase and α1,3 fucosyltransferase and the second polypeptide comprises an immune response stimulator polypeptide.
A purified tumor vaccine comprising:
- (a) an adjuvant polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is a mucin polypeptide and is glycosylated by a α1,2 fucosyltransferase and α1,3 fucosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide and
- (b) an immune response stimulator polypeptide.
A method of increasing immune cell activation, comprising contacting said immune cell with a purified tumor vaccine, said tumor vaccine comprising a polypeptide, wherein the polypeptide is glycosylated by a α1,2 fucosyltransferase and α1,3 fucosyltransferase, such that the activation of said cell is increased.
Dependencies are inferred from the claim text.